Publications by authors named "D M G Halpin"

To optimize patient outcomes, healthcare decisions should be based on the most up-to-date high-quality evidence. Randomized controlled trials (RCTs) are vital for demonstrating the efficacy of interventions; however, information on how an intervention compares to already available treatments and/or fits into treatment algorithms is sometimes limited. Although different therapeutic classes are available for the treatment of chronic obstructive pulmonary disease (COPD), assessing the relative efficacy of these treatments is challenging.

View Article and Find Full Text PDF

Chronic obstructive pulmonary disease (COPD) is a heterogenous lung condition characterized by progressive airflow obstruction. Despite advancements in diagnosis and treatment, the disease burden remains high; although clinical trials have shown improvements in outcomes such as exacerbations, quality of life, and lung function, improvement may not be attainable for many patients. For patients who do experience improvement, it is challenging to set management goals given the progressive nature of COPD.

View Article and Find Full Text PDF

The Global initiative for chronic Obstructive Lung Disease (GOLD) report states that the diagnosis of chronic obstructive pulmonary disease (COPD) should be considered in individuals with chronic respiratory symptoms and / or exposure to risk factors. Forced spirometry demonstrating airflow obstruction after bronchodilation is required to confirm the diagnosis using a threshold of forced expiratory volume in 1 s (FEV) / forced vital capacity (FVC) ratio<0.7.

View Article and Find Full Text PDF
Article Synopsis
  • COPD has high mortality rates, especially when combined with cardiovascular disease, leading to an exploration of ECG markers (CIIS and P pulmonale) as predictors of adverse events in COPD patients.
  • A study involving 9448 patients revealed that those with CIIS ≥20 or P pulmonale had significantly higher odds of all-cause death, hospitalizations, and severe COPD exacerbations compared to those without these markers.
  • The findings indicate that using CIIS and P pulmonale could help identify patients at increased risk, and treatment with FF/UMEC/VI may reduce risks in patients with CIIS ≥20.
View Article and Find Full Text PDF